A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
Novartis
Tempus AI
Ohio State University Comprehensive Cancer Center
Revolution Medicines, Inc.
Dublin City University
Oslo University Hospital